(Q30559275)

English

Resistance to targeted therapies in pancreatic neuroendocrine tumors (PNETs): molecular basis, preclinical data, and counteracting strategies

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

24 June 2017

Resistance to targeted therapies in pancreatic neuroendocrine tumors (PNETs): molecular basis, preclinical data, and counteracting strategies (English)

1 reference

Europe PubMed Central

PubMed publication ID

24 June 2017

Annemilaï Tijeras-Raballand

1

object named as

Annemilaï Tijeras-Raballand

0 references

Cindy Neuzillet

2

object named as

Cindy Neuzillet

1 reference

Europe PubMed Central

PubMed publication ID

24 June 2017

3

object named as

Anne Couvelard

1 reference

Europe PubMed Central

PubMed publication ID

24 June 2017

author name string

Annemilaï Tijeras-Raballand

1

1 reference

Europe PubMed Central

PubMed publication ID

24 June 2017

Maria Serova

4

1 reference

Europe PubMed Central

PubMed publication ID

24 June 2017

Armand de Gramont

5

1 reference

Europe PubMed Central

PubMed publication ID

24 June 2017

Pascal Hammel

6

1 reference

Europe PubMed Central

PubMed publication ID

24 June 2017

Eric Raymond

7

1 reference

Europe PubMed Central

PubMed publication ID

24 June 2017

Sandrine Faivre

8

1 reference

Europe PubMed Central

PubMed publication ID

24 June 2017

publication date

25 August 2012

1 reference

Europe PubMed Central

PubMed publication ID

24 June 2017

Targeted oncology

1 reference

Europe PubMed Central

PubMed publication ID

24 June 2017

7

1 reference

Europe PubMed Central

PubMed publication ID

24 June 2017

3

1 reference

Europe PubMed Central

PubMed publication ID

24 June 2017

173-181

1 reference

Europe PubMed Central

PubMed publication ID

24 June 2017

Sunitinib malate for the treatment of pancreatic neuroendocrine tumors

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0229-6

21 January 2018

Everolimus for advanced pancreatic neuroendocrine tumors.

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0229-6

21 January 2018

Modes of resistance to anti-angiogenic therapy

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0229-6

21 January 2018

Hallmarks of Cancer: The Next Generation

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0229-6

21 January 2018

Basic and therapeutic aspects of angiogenesis

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0229-6

21 January 2018

Tumor angiogenesis: molecular pathways and therapeutic targets

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0229-6

21 January 2018

Mechanisms of mTOR inhibitor resistance in cancer therapy

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0229-6

21 January 2018

Current development of mTOR inhibitors as anticancer agents

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0229-6

21 January 2018

Structure of the FKBP12-rapamycin complex interacting with the binding domain of human FRAP

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0229-6

21 January 2018

Predictive biomarkers for the activity of mammalian target of rapamycin (mTOR) inhibitors

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0229-6

21 January 2018

Gastroenteropancreatic neuroendocrine tumors: indications for and pitfalls of frozen section examination.

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0229-6

21 January 2018

Overexpression of the oxygen sensors PHD-1, PHD-2, PHD-3, and FIH Is associated with tumor aggressiveness in pancreatic endocrine tumors

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0229-6

21 January 2018

von Hippel-Lindau disease

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0229-6

21 January 2018

Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0229-6

21 January 2018

Heritable formation of pancreatic beta-cell tumours in transgenic mice expressing recombinant insulin/simian virus 40 oncogenes

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0229-6

21 January 2018

Antiangiogenic therapy of transgenic mice impairs de novo tumor growth

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0229-6

21 January 2018

Effects of angiogenesis inhibitors on multistage carcinogenesis in mice

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0229-6

21 January 2018

Survival Benefit With Proapoptotic Molecular and Pathologic Responses From Dual Targeting of Mammalian Target of Rapamycin and Epidermal Growth Factor Receptor in a Preclinical Model of Pancreatic Neuroendocrine Carcinogenesis

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0229-6

21 January 2018

Elevated levels of IGF-1 receptor convey invasive and metastatic capability in a mouse model of pancreatic islet tumorigenesis

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0229-6

21 January 2018

Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0229-6

21 January 2018

VEGF-A has a critical, nonredundant role in angiogenic switching and pancreatic beta cell carcinogenesis

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0229-6

21 January 2018

Stage-specific vascular markers revealed by phage display in a mouse model of pancreatic islet tumorigenesis

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0229-6

21 January 2018

Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0229-6

21 January 2018

Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR.

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0229-6

21 January 2018

Akt activation in renal cell carcinoma: contribution of a decreased PTEN expression and the induction of apoptosis by an Akt inhibitor

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0229-6

21 January 2018

Bcl-2 and CCND1/CDK4 expression levels predict the cellular effects of mTOR inhibitors in human ovarian carcinoma

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0229-6

21 January 2018

Brivanib, a dual FGF/VEGF inhibitor, is active both first and second line against mouse pancreatic neuroendocrine tumors developing adaptive/evasive resistance to VEGF inhibition

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0229-6

21 January 2018

Efficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: a phase II study

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0229-6

21 January 2018

Epithelial-to-mesenchymal transition and acquired resistance to sunitinib in a patient with hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0229-6

21 January 2018

The antitumor effects of sunitinib (formerly SU11248) against a variety of human hematologic malignancies: enhancement of growth inhibition via inhibition of mammalian target of rapamycin signaling

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0229-6

21 January 2018

Developmental arrest of angioblastic lineage initiates tumorigenesis in von Hippel-Lindau disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/22923165

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Metabolism and disposition of [14C]brivanib alaninate after oral administration to rats, monkeys, and humans

1 reference

https://pubmed.ncbi.nlm.nih.gov/22923165

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S11523-012-0229-6

1 reference

Europe PubMed Central

PubMed publication ID

24 June 2017

Dimensions Publication ID

0 references

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

24 June 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q30559275&oldid=2194934640"